NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

NEULAND

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2018

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED	
		Quarter Ended		Year Ended		Year Ended	
		31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)
1	Revenue from operations	16,022.62	14,154.79	52,916.15	58,772.51	52,916.15	58,772.51
2	Net profit for the period (before tax and exceptional items)	859.19	1,867.30	1,354.03	6,655.17	1,393.44	6,718.57
3	Net profit for the period before tax	859.19	1,867.30	1,354.03	6,655.17	1,393.44	6,718.57
4	Net profit for the period after tax	805.29	1,468.84	1,180.81	4,638.40	1,206.28	4,686.46
5	Total comprehensive income for the period	841.50	1,501.97	1,200.35	4,654.86	1,242.59	4,692.59
6	"Paid-up Equity Share Capital (Face value - ₹10 each)"	895.49	895.49	895.49	895.49	895.49	895.49
7	Other equity			23,497.52	22,297.17	23,823.80	22,581.20
8	Equity suspense account			31,084.99	31,084.99	31,084.99	31,084.99
9	"Earnings Per Share (of ₹10 each) (in absolute ₹ terms)"						
	(a) Basic	7.22	13.17	10.59	41.58	10.81	42.01
	(b) Diluted	7.22	13.17	10.59	41.58	10.81	42.01

Note: The above is an extract of the detailed format of Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Annual Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Sd/-
Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 11 May 2018

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

NEULAND

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2018

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED	
		Quarter Ended		Year Ended		Year Ended	
		31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)
1	Revenue from operations	16,022.62	14,154.79	52,916.15	58,772.51	52,916.15	58,772.51
2	Net profit for the period (before tax and exceptional items)	859.19	1,867.30	1,354.03	6,655.17	1,393.44	6,718.57
3	Net profit for the period before tax	859.19	1,867.30	1,354.03	6,655.17	1,393.44	6,718.57
4	Net profit for the period after tax	805.29	1,468.84	1,180.81	4,638.40	1,206.28	4,686.46
5	Total comprehensive income for the period	841.50	1,501.97	1,200.35	4,654.86	1,242.59	4,692.59
6	"Paid-up Equity Share Capital (Face value - ₹10 each)"	895.49	895.49	895.49	895.49	895.49	895.49
7	Other equity			23,497.52	22,297.17	23,823.80	22,581.20
8	Equity suspense account			31,084.99	31,084.99	31,084.99	31,084.99
9	"Earnings Per Share (of ₹10 each) (In absolute ₹ terms)"						
	(a) Basic	7.22	13.17	10.59	41.58	10.81	42.01
	(b) Diluted	7.22	13.17	10.59	41.58	10.81	42.01

Note: The above is an extract of the detailed format of Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Annual Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Sd/-
Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 11 May 2018